A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
Janssen-Cilag Ltd.
200 participants
Apr 17, 2026
OBSERVATIONAL
Conditions
Summary
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07532226